Literature DB >> 2784720

Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combined immunodeficiency (scid) and athymic (nude) mice.

M Hasui1, Y Saikawa, M Miura, N Takano, Y Ueno, A Yachie, T Miyawaki, N Taniguchi.   

Abstract

The lineage of lymphokine-activated killer (LAK) cells is poorly understood. To examine the relationship between LAK and natural killer (NK) cells we utilized two congenitally immunodeficient mice, namely severe combined immunodeficient (scid) and athymic (nude) mice that lack T cells but have normal NK cells. LAK activity was evaluated by the ability to lyze NK-resistant P815 cells. When cultured with human recombinant interleukin 2, splenocytes of scid and nude mice could generate LAK activity at levels comparable to or more than those of normal C.B-17 mice. LAK effector cells in these immunodeficient mice as well as normal mice had the phenotype resembling that of NK cells with asialo-GM1 (aGM1) expression. In vivo treatment with anti-aGM1 antiserum completely abolished the induction of LAK activity from splenocytes of normal mice. In contrast, LAK activity in splenocytes of scid and nude mice was still demonstrable even after this treatment, indicating that most LAK precursors in both mice were cells without aGM1 antigen. The aGM1- progenitors for LAK activity, probably in common with NK progenitors, appeared to be more expanded in scid and nude mice than in normal mice. The use of such congenitally immunodeficient mice should be helpful in studying the differentiation step of LAK as well as NK cells from their precursors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784720     DOI: 10.1016/0008-8749(89)90190-1

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

1.  Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.

Authors:  Rodney B Luwor; Yang Lu; Xinqun Li; Ke Liang; Zhen Fan
Journal:  Cancer Lett       Date:  2011-03-15       Impact factor: 8.679

2.  IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid.

Authors:  D Croxatto; S Martini; L Chiossone; F Scordamaglia; C F Simonassi; L Moretta; M C Mingari; P Vacca
Journal:  Oncoimmunology       Date:  2017-02-17       Impact factor: 8.110

3.  The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.

Authors:  Nathalie Kersual; Véronique Garambois; Thierry Chardès; Jean-Pierre Pouget; Imed Salhi; Caroline Bascoul-Mollevi; Frédéric Bibeau; Muriel Busson; Henri Vié; Béatrice Clémenceau; Christian K Behrens; Pauline Estupina; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  MAbs       Date:  2014       Impact factor: 5.857

4.  Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.

Authors:  Y F Zhai; W J Esselman; C S Oakley; C C Chang; C W Welsch
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 5.  Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines.

Authors:  R Clarke
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Antitumor response independent of functional B or T lymphocytes induced by the local and sustained release of interleukin-2 by the tumor cells.

Authors:  T Alosco; B A Croy; B Gansbacher; H Q Wang; U Rao; R Bankert
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

7.  Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection.

Authors:  G Karupiah; R V Blanden; I A Ramshaw
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.